Psychology & Neuroscience, Vol 17(4), Dec 2024, 302-313; doi:10.1037/pne0000342Objective: Severe acute respiratory syndrome coronavirus 2 may result in persistent physical, psychological, and/or cognitive symptoms, termed postacute sequelae of COVID-19 (PASC). A growing literature has documented the presence of cognitive deficits in individuals diagnosed with PASC; however, the use of performance validity tests (PVTs) has varied widely. The present study characterized base rates of PVT failure in patients with PASC. Method: The sample consisted of 91 adults with PASC referred for clinical neuropsychological evaluation between May 2021 and September 2023. Patients were administered a battery of neuropsychological tests, self-report symptom checklists, and two or more PVTs, including the Test of Memory Malingering Trial 1; Medical Symptom Validity Test; Digit Span Age-Corrected Scaled Score and Reliable Digit Span; and either California Verbal Learning Test, Third Edition, Recognition Hits and Forced-Choice Recognition (FCR) or Hopkins Verbal Learning Test–Revised Recognition Discriminability and FCR. Results: Using a threshold of ≥ 2 PVT failures, nine patients (9.9%) were classified as having invalid performance when using more conservative dichotomous cutoffs for individual PVTs, and 13 patients (14.3%) were classified when using more liberal cutoffs. When using trichotomous cutoffs, 25 patients’ performances (27.5%) were considered borderline, and eight (8.8%) were considered invalid. Conclusions: These findings indicate that PVT failure in patients with PASC is relatively uncommon, but these findings, nonetheless, highlight the importance of including PVTs in clinical and research settings when assessing cognition in those with PASC. (PsycInfo Database Record (c) 2024 APA, all rights reserved)
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: | September 5, 2024